Hakan Korkmaz1, Suzan Tabur2, Esen Savaş3, Mesut Özkaya2, Şefika Nur Aksoy4, Nurten Aksoy5, Ersin Akarsu2. 1. Department of Endocrinology and Metabolic Disease, Edirne State Hospital, Edirne, Turkey. 2. Division of Endocrinology, Department of Internal Medicine, Gaziantep University School of Medicine, Gaziantep, Turkey. 3. Department of Internal Medicine, Gaziantep University School of Medicine, Gaziantep, Turkey. 4. Department of Clinical Biochemistry, Gaziantep University School of Medicine, Gaziantep, Turkey. 5. Department of Clinical Biochemistry, Harran University School of Medicine, Şanlıurfa, Turkey.
Abstract
BACKGROUND: The correlation of S100A8/S100A9 with various inflammatory conditions, including autoimmune diseases have been reported. There is no study investigating the levels of S100A8/S100A9 in autoimmune thyroid diseases (AITD). AIMS: We aimed to evaluate the level of serum S100A8/S100A9 in AITD. STUDY DESIGN: Case control study. METHODS: Fifty patients with AITD (25 Hashimoto's thyroiditis (HT) and 25 Graves' disease (GD)) were included in the study. Twenty seven healthy subjects participated as a control group. Blood samples were obtained in the 3 months after the initiation of medical treatment. Serum levels of total antioxidant status (TAS), total oxidative status (TOS), total free sulfhydryl (SH), lipid hydroperoxide (LOOH) and S100A8/S100A9 were analyzed. RESULTS: The patients with AITD had significantly higher S100A8/S100A9, OSI, LOOH and TOS levels than the healthy control group. There was no significant difference between GD and HT patients in terms of S100A8/S100A9, TOS and OSI levels. S100A8/S100A9 level was positively correlated with LOOH, TOS and OSI levels but negatively correlated with -SH level in the patients with AITD. CONCLUSION: Serum S100A8/S100A9 levels were increased in patients with AITD and positively correlated with LOOH, TOS and OSI whereas negatively correlated with SH.
BACKGROUND: The correlation of S100A8/S100A9 with various inflammatory conditions, including autoimmune diseases have been reported. There is no study investigating the levels of S100A8/S100A9 in autoimmune thyroid diseases (AITD). AIMS: We aimed to evaluate the level of serum S100A8/S100A9 in AITD. STUDY DESIGN: Case control study. METHODS: Fifty patients with AITD (25 Hashimoto's thyroiditis (HT) and 25 Graves' disease (GD)) were included in the study. Twenty seven healthy subjects participated as a control group. Blood samples were obtained in the 3 months after the initiation of medical treatment. Serum levels of total antioxidant status (TAS), total oxidative status (TOS), total free sulfhydryl (SH), lipid hydroperoxide (LOOH) and S100A8/S100A9 were analyzed. RESULTS: The patients with AITD had significantly higher S100A8/S100A9, OSI, LOOH and TOS levels than the healthy control group. There was no significant difference between GD and HTpatients in terms of S100A8/S100A9, TOS and OSI levels. S100A8/S100A9 level was positively correlated with LOOH, TOS and OSI levels but negatively correlated with -SH level in the patients with AITD. CONCLUSION: Serum S100A8/S100A9 levels were increased in patients with AITD and positively correlated with LOOH, TOS and OSI whereas negatively correlated with SH.
Entities:
Keywords:
Autoimmune thyroid disease; S100A8/S100A9; oxidative status
Authors: L van Bon; M Cossu; A Loof; F Gohar; H Wittkowski; M Vonk; J Roth; W van den Berg; W van Heerde; J C A Broen; T R D J Radstake Journal: Ann Rheum Dis Date: 2014-04-09 Impact factor: 19.103
Authors: Helena Tydén; Christian Lood; Birgitta Gullstrand; Andreas Jönsen; Ola Nived; Gunnar Sturfelt; Lennart Truedsson; Fredrik Ivars; Tomas Leanderson; Anders A Bengtsson Journal: Rheumatology (Oxford) Date: 2013-08-13 Impact factor: 7.580